BDBernard Denis

Bernard Denis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bernard Denis has a total of 313 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of serrated lesion detection using different indicators: a single-centre, community-based, retrospective cohort study

    by Bernard Denis, Vigueneche Catinat, Laurianne Plastaras, Izabella Amaritei, Marion Bolliet, Mathilde Clavel, Rémi Darrius, Paul Montet, Sebastian Vuola, Leslie Simomia Mbowen, et al.

    Objective: There are inverse associations between both the adenoma detection rate (ADR) and the serrated lesion detection rate (SLDR) and the risk of postcolonoscopy colorectal cancer. We aimed to evaluate the SLDRs of community endoscopists and to define the most relevant quality indicator for this. Methods: A retrospective analysis was conducted on adults undergoing colonoscopy from January 2023 to June 2024 at a community hospital. ADR, sessile, proximal, large, clinically relevant and advanced SLDRs were assessed. Results: Overall, 1871 colonoscopies were evaluated, performed by 11 endoscopists. The overall ADR, sessile and proximal SLDR were respectively 27.0% (95% CI 24.6% to 29.8%), 7.0% (95% CI 5.5% to 8.4%) and 8.9% (95% CI 7.4% to 10.3%). A third of endoscopists had suboptimal SLDRs. The correlation between ADR and sessile SLDR was moderate and non-significant (r=0.57, p=0.07) but was excellent between sessile and proximal SLDR (r=0.93, p11 min vs 11 min was associated with a doubling of ADR and proximal SLDR compared with <9 min. In routine practice, the sessile and proximal SLDRs seem to be similar for assessing the detection of serrated lesions and should become major quality indicators for colonoscopy.

  • Detection of faecal blood outside organised screening programmes: the vital role of medical biologists

    by Bernard Denis, Callum G Fraser

    Outside organised colorectal cancer (CRC) screening programmes, faecal occult blood testing helps general practitioners decide whether to refer symptomatic patients for a colonoscopy. In France, practices vary widely, have not been evaluated, and are based on several qualitative and quantitative faecal immunochemical tests (FITs) with very different performance characteristics that clinicians do not appreciate. In the United Kingdom, this practice is generally based on two recommended automated quantitative FITs and usually follows very specific recommendations. Quantitative FITs have been extensively evaluated and have demonstrated their superiority, both in organised CRC screening programmes and in the investigation of symptomatic patients, albeit with different decision thresholds. In a symptomatic patient, the threshold of 10 μg haemoglobin/gram of faeces (μg/g) from the English guidelines is not applicable in France. We suggest a threshold of 2 μg/g, offering a sensitivity of 94.7 % for the diagnosis of CRC, which must be confirmed by further studies in the French symptomatic population. The advantages of quantitative faecal immunochemical tests (FIT) are such that they will gradually replace qualitative FITs: self-collection, a single sample, at most two, lower cost, control of the pre-analytical phase, automation, a significant reduction in equivocal and uninterpretable results, control of the positivity threshold, information on the degree of urgency of colonoscopy, better analytical and clinical performance, and better cost-effectiveness ratio. It is urgent that the French National Authority for Health (HAS) draw up recommendations and a framework for use in symptomatic patients and update the nomenclature of medical biology procedures.

  • Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study

    by Adrien Grancher, Bernard Denis, Julie Plaine, Somany Vidal-Sengchanh, Marie-Christine Quertier, Cécile Quintin, Lydia Guittet

    Background: Depending on the colorectal cancer (CRC) screening programme, a colonoscopy should be performed within 1–3 months after a positive faecal immunochemical test (FIT) result. However, such short timescales may be difficult to meet and seem trivial when most CRCs take years to develop. Objective: To assess the impact of time to colonoscopy on CRC outcomes. Design: This French nationwide retrospective cohort study included individuals with a positive FIT result between 2016 and 2019 and a subsequent colonoscopy performed within 24 months. The risks of CRC, advanced-stage CRC and advanced adenoma (AA) according to time interval to colonoscopy were assessed and evaluated on individual and socio-geographic characteristics. Results: Overall, 374 113 FIT-positive individuals underwent post-FIT colonoscopy (86.6% compliance rate), with 21 616 CRCs and 122 359 AAs diagnosed. Compared with the 2–3 months interval class, no increased risk of CRC, advanced-stage CRC or AA was observed after 3 months up to 24 months, with adjusted odds ratio after 12 months at 0.93 (0.95 CI 0.83 to 1.03), 1.04 (0.85 to 1.25) and 0.88 (0.82 to 0.93), respectively. Individuals with high faecal haemoglobin concentrations (f-Hb ≥200 µg/g) were respectively eight, eleven and two times more likely to have a CRC, an advanced-stage CRC or an AA as compared with the 30–40 µg/g class. Conclusion: No increased risk of CRC, advanced-stage CRC or AA was observed up to 24 months. Our findings suggest that ensuring colonoscopy compliance after a positive FIT may take precedence over rigid adherence to interval. The higher the f-Hb, the sooner the colonoscopy should be performed.


  • Open Access

    Systematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First‐Line Treatment: A Cohort Study

    by Bernard Denis, Laurianne Plastaras, Izabella Amaritei, Marion Bolliet, Mathilde Clavel, Rémi Darrius, Paul Montet, Sebastian Vuola, Dominique de Briel

    Background: European guidelines recommend that susceptibility tests be routinely performed, even before prescribing first‐line treatment of Helicobacter pylori infection. However, empirical treatments are the rule in France, and susceptibility‐guided treatments are the exception. Objective: We aimed to report our experience of systematic antibiotic susceptibility testing before first‐line treatment. Methods: Prospective registration of all esofagogastroduodenoscopies performed in a community hospital from December 2023 to December 2024. Antral and fundic biopsies were performed, at the discretion of the endoscopist, for histological examination, polymerase chain reaction (PCR) and culture without any freezing. Results: Overall, 3566 adults underwent esofagogastroduodenoscopy, 1785 (50.1%) were tested and H. pylori infection was diagnosed in 308 (17.3%) [95% confidence interval (CI): 15.5%–19.0%] individuals. The sensitivity of PCR for the diagnosis of H. pylori infection was 99.7%, significantly higher than those of histology (94.1%) and culture (95.2%) ( p < 0.01). Clarithromycin resistance was observed in 22.6% [95% CI: 17.9%–27.3%] and levofloxacin resistance in 18.6% [95% CI: 14.1%–23.2%] of cases. Among 285 patients treated, susceptibility‐guided triple therapy was prescribed in 84.9% of cases (73.3% amoxicillin‐clarithromycin, 11.6% amoxicillin‐levofloxacin) and quadruple bismuth therapy in 14.4% of cases. The eradication rates were 98.1% [95% CI: 96.0%–100%] for triple therapy amoxicillin‐clarithromycin and 100% [95% CI: 100%–100%] for amoxicillin‐levofloxacin, significantly higher than 81.3% [95% CI: 67.7%–94.8%] for quadruple bismuth therapy ( p < 0.01 and p = 0.03, respectively). Overall, of 218 (70.8%) patients evaluated by the C13 urea breath test, H. pylori was eradicated in 209 (95.9%) [95% CI: 93.2%–98.5%] patients. The PCR‐based diagnostic and therapeutic strategy was more cost‐effective than the immunohistochemistry‐based strategy. Conclusion: A PCR‐based susceptibility‐guided strategy is easy to implement in routine clinical practice. In more than 7 in 10 patients, PCR enabled the offer of a susceptibility‐guided triple therapy that was more effective and less costly than empirical quadruple bismuth therapy. Culture enabled one additional patient in 10 to be offered a susceptibility‐guided triple therapy.